innoVitro GmbH

Juelich,  NRW 
  • Booth: 543

innoVitro is a german CRO, providing human-based cardiac risk screening services for Pharma, Biotech and Academia worldwide. Screening parameters encompass structural and functional parameters analysed with a high throughput 96-well hybrid system consisting of the CardioExcyte and the proprietary FLEXcyte 96 technology. Either one or both technologies can be applied for addressing drug-induced changes of healthy or diseased hiPSC-cardiomyocytes regarding morphological and contractile changes.

Send Email

Type your information and click "Send Email" to send an email to this exhibitor. To return to the previous screen without saving, click "Reset".